ESMO 2025: Novartis’s Pluvicto delays progression to end-stage for mHSPC

The number of diagnosed prevalent drug-treated mHSPC cases in the 8MM will rise from 196,867 in 2025 to 244,101 by 2033.
Cantech Letter

Talon Metals Receives Extension from Kennecott Exploration to Ensure Alignment of the Tamarack Nickel Copper Project's Feasibility Study with Environmental Review

Key Environmental Review Milestone Expected in H1 2026; 12-Month Extension Provided for Talon’s Earn-in to 60% Ownership in Tamarack Nickel Copper Project Tamarack, Minnesota–(Newsfile Corp.
Targeted Oncology

Apalutamide/ADT Improves Long-Term Outcomes in Biochemically Recurrent Prostate Cancer

Adding apalutamide (Erleada) to androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer reduced the risk of developing metastases and castration-resistant disease, ...